New therapies for obesity
Open accessThe DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic disease associated with serious complications and increased mortality. Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to compensatory biological adaptations (increased appetite and reduced energy expenditure) promoting weight gain. Bariatric surgery was until recently the only intervention that consistently resulted in ≥ 15% WL and maintenance. Our better understanding of the endocrine regulation of appetite has led to the development of new medications over the last decade for the treatment of obesity with main target the reduction of appetite. The efficacy of semaglutide 2.4 mg/week—the latest glucagon-like peptide-1 (GLP-1) receptor analogue—on WL for people with obesity suggests that we are entering a new era in obesity pharmacotherapy where ≥15% WL is feasible. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The effect of different weight loss interventions [low-calorie diet, exercise, pharmacotherapy (GLP-1 receptor analogues), and bariatric surgery] on appetite.](https://figures.cochat.ai/paper-figures/74f216bb7eab42a2a84eb3e4b32f20c9/new-therapies-for-obesity-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Around 10–30% of participants (especially people with T2D) achieved <10% WL in clinical trials even with the higher doses of the new pharmacotherapies [101, 102].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple other molecules (including combinations of entero-pancreatic hormones and oral GLP-1 RA) are in late phase clinical trials as potential obesity treatments, leading to WL that approaches the efficacy of bariatric surgery [101].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Despite that sleeve gastrectomy and gastric bypass, the two most commonly performed bariatric procedures today, can result in sustained long-term WL ≥ 20–25% in people with obesity and T2D and in multiple cardiometabolic benefits, bariatric surgery is an intervention which is not scalable in population level and people can be hesitant to this option due to the risk of postoperative complications [”
The cited source says what the claim attributes to it.
In the citing paper
“Despite that sleeve gastrectomy and gastric bypass, the two most commonly performed bariatric procedures today, can result in sustained long-term WL ≥ 20–25% in people with obesity and T2D and in multiple cardiometabolic benefits, bariatric surgery is an intervention which is not scalable in population level and people can be hesitant to this option due to the risk of postoperative complications [”
In the citing paper
“Despite that sleeve gastrectomy and gastric bypass, the two most commonly performed bariatric procedures today, can result in sustained long-term WL ≥ 20–25% in people with obesity and T2D and in multiple cardiometabolic benefits, bariatric surgery is an intervention which is not scalable in population level and people can be hesitant to this option due to the risk of postoperative complications [”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
Hills, A. P., Byrne, N. M., Lindstrom, R., & Hill, J. O. (2013) · Obesity Facts · doi:10.1159/000345030 · Cited by 9,493
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“68 On the other hand, in the STEP-3 study where semaglutide 2.4 mg was combined with IBT and an 8-week low-calorie diet, 15,73 the WL achieved at 68 weeks was similar to the WL reported when Semaglutide 2.4 mg was combined with a 500 kcal/day deficit diet 15 (16 vs. 14.9”
BackgroundMethodInfluentialSelf-citationProspective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 1×
“…associated with improvement in QoL and obesity-related complications, reduction by 53% in fatal and 33% in total cardiovascular events, and reduction by 29% in mortality compared with the usual care group, 11,12,46,47 providing a WL threshold associated with multiple clinically important benefits.”
BackgroundLifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“77 Other dual co-agonists acting on GLP-1/amylin receptors and GLP-1/ glucagon receptors are also being assessed in early phase clinical trials as potential treatments for obesity and metabolic complications.”
BackgroundHaslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“95 98 GLP-1 RAs have been developed initially for the treatment of T2D, however due to their efficacy in inducing WL and reducing appetite, they have been repurposed in higher doses as treatments for obesity.”
BackgroundSelf-citationCardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 2×
“…interventions (500 kcal deficit diet plus advise for physical activity or intensive behavioural therapy) plus placebo (green background), 15,62,65–68,70 ( B ) liraglutide 3 mg, marked improvements both on WL and glycaemia, despite that tirzepatide in SURPASS programme was not combined with…”
BackgroundInfluentialYears of Life Lost Due to Obesity
Fontaine, K. R., Redden, D. T., Wang, C., Westfall, A. O., & Allison, D. B. (2003) · JAMA · doi:10.1001/jama.289.2.187 · Cited by 2,495
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 2×
“83,121 Tirzepatide is a once weekly unimolecular agonist of both GLP-1 and GIP receptors which has a deliberate bias towards GIP over GLP-1 activity (it possesses five-fold increased relative potency at human GIP receptor when compared with GLP-1 receptor).”
BackgroundInfluentialSelf-citationSjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835 · cited 5×
“11,45 In the Swedish obese subjects (SOS) study, bariatric surgery was able to induce and maintain ≥ 15% mean WL over 20 years follow-up (compared with 1% WL at the usual care group).”
BackgroundInfluentialBariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656 · cited 1×
“…associated with improvement in QoL and obesity-related complications, reduction by 53% in fatal and 33% in total cardiovascular events, and reduction by 29% in mortality compared with the usual care group, 11,12,46,47 providing a WL threshold associated with multiple clinically important benefits.”
BackgroundBray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 3×
“35 Potential mediators of the increased appetite are the elevated levels of the hunger hormone ghrelin as well as the reduction in leptin and perhaps also satiety gut hormones such as peptide YY (PYY), amylin, and cholecystokinin.”
BackgroundInfluentialRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · cited 2×
“74 These results suggest that ongoing treatment is required to maintain improvements in weight, although this topic so far has been poorly explored.”
BackgroundInfluentialSelf-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Self-citationWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 6×
“44 One year after withdrawal of sema-glutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior WL resulting in final total WL of 5.6% from baseline weight.”
BackgroundMethodInfluentialSelf-citationWadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 3×
“58 Today, good quality evidence is lacking regarding the cardio-vascular benefits of the approved pharmacotherapies for obesity as discussed before, although the results of the cardiovascular outcome trials conducted in people with T2D are likely to also apply to people with obesity.”
BackgroundRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 3×
“14,85,86 Decreased appetite was also a commonly reported side effect.”
BackgroundGadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036 · cited 2×
“65,79 The NB is contraindicated in people with epilepsy as buproprion is associated with dose-related risk of seizures.”
BackgroundAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 1,017 · cited 1×
“16,17 In the DROPLET study, a community delivered, low energy (810 kcal/day) total diet replacement programme with formula products as the sole food during the first 8 weeks followed by food reintroduction resulted in mean WL of 10.7 kg at 12 months compared with 3.1 kg at the usual care group in…”
MethodInfluentialRubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“57,58 More recently, lorcaserin was withdrawn from the market because of a signal of increased cancer risk.”
BackgroundCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“122 This has been provided as a potential explanation for the more prominent effects on weight and glucose compared with the more balanced dual agonists targeting GLP-1 and GIP receptors equally (although this is difficult to understand given that GIP alone has no effect on food intake in man).”
BackgroundMaintenance of Lost Weight and Long-Term Management of Obesity
Hall, K. D., & Kahan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.012 · Cited by 876 · cited 1×
“29 Only 10–25% of individuals who will undergo different intensity lifestyle interventions will be able to lose and maintain ≥ 10% WL long-term.”
BackgroundThe Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It
The Look AHEAD Research Group (2006) · Obesity · doi:10.1038/oby.2006.84 · Cited by 873 · cited 1×
“16,17 In the DROPLET study, a community delivered, low energy (810 kcal/day) total diet replacement programme with formula products as the sole food during the first 8 weeks followed by food reintroduction resulted in mean WL of 10.7 kg at 12 months compared with 3.1 kg at the usual care group in…”
MethodInfluentialKhera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865 · cited 1×
“60 Over the past decade, several agents that act by reducing hunger or promote satiation have been approved by regulatory authorities worldwide for chronic weight management, including phentermine plus topiramate (approved only in the USA), bupropion plus naltrexone, and the GLP-1 RAs liraglutide 3…”
Backgroundle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842 · cited 3×
“8 24–26 However, in a post-hoc analysis, those participants in the intervention arm who lost ≥ 10% of their baseline body weight during the first year (early good responders) had 20% lower risk for cardiovascular events over a 10 years follow-up period.”
BackgroundInfluentialFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1×
“83,121 Tirzepatide is a once weekly unimolecular agonist of both GLP-1 and GIP receptors which has a deliberate bias towards GIP over GLP-1 activity (it possesses five-fold increased relative potency at human GIP receptor when compared with GLP-1 receptor).”
BackgroundThe Look AHEAD Research Group (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00064-3 · Cited by 767 · cited 1×
“23 The intensive lifestyle group lost 8.6% of their initial body weight at 1 year and 4.7% at 8 years while the usual care arm lost 0.7% at 1 year and 2.1% at 8 years.”
BackgroundInfluentialGut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., Lönroth, H., Fändriks, L., Ghatei, M. A., Bloom, S. R., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180caa3e3 · Cited by 741 · cited 1×
“11,45 In the Swedish obese subjects (SOS) study, bariatric surgery was able to induce and maintain ≥ 15% mean WL over 20 years follow-up (compared with 1% WL at the usual care group).”
Background(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711 · cited 1×
“…interventions (500 kcal deficit diet plus advise for physical activity or intensive behavioural therapy) plus placebo (green background), 15,62,65–68,70 ( B ) liraglutide 3 mg, marked improvements both on WL and glycaemia, despite that tirzepatide in SURPASS programme was not combined with…”
BackgroundDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684 · cited 1×
“14,85,86 Decreased appetite was also a commonly reported side effect.”
BackgroundPersistent metabolic adaptation 6 years after “The Biggest Loser” competition
Fothergill, E., Guo, J., Howard, L., Kerns, J. C., Knuth, N. D., Brychta, R., Chen, K. Y., Skarulis, M. C., Walter, M., Walter, P. J., et al. (2016) · Obesity · doi:10.1002/oby.21538 · Cited by 672 · cited 2×
“33,34 In addition, most people who manage to lose ≥ 10% of their body weight through low-calorie diet experience an increase in their appetite compared with baseline ( Figure 1 ).”
BackgroundLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1×
“123 The phase 3 trials with tirzepatide doses 5–15 mg in people with T2D who are overweight or have obesity (SURPASS programme) have shown”
BackgroundSelf-citationvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“31,40 43 However, as with most management techniques for chronic diseases, obesity relapses if the treatment is stopped.”
BackgroundHealthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · cited 3×
“21 Further studies are necessary to help us understand how to best combine the new pharmacotherapies with different lifestyle interventions not only to maximize WL, but also to optimize body composition and health benefits.”
BackgroundInfluentialSelf-citationLife expectancy after bariatric surgery in the Swedish obese subjects study
Carlsson, L. M. S., Sjöholm, K., Jacobson, P., Andersson-Assarsson, J. C., Svensson, P.-A., Taube, M., Carlsson, B., & Peltonen, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002449 · Cited by 509 · cited 1×
“…associated with improvement in QoL and obesity-related complications, reduction by 53% in fatal and 33% in total cardiovascular events, and reduction by 29% in mortality compared with the usual care group, 11,12,46,47 providing a WL threshold associated with multiple clinically important benefits.”
BackgroundDavies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationAminian, A., Zajichek, A., Arterburn, D. E., Wolski, K. E., Brethauer, S. A., Schauer, P. R., Kattan, M. W., & Nissen, S. E. (2019) · JAMA · doi:10.1001/jama.2019.14231 · Cited by 505 · cited 1×
“50,51 The most commonly performed bariatric procedures in the SOS study were gastric band and vertical banded gastroplasty with fewer patients undergoing Roux-en-Y gastric bypass (RYGB).”
BackgroundHollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501
Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W. K., Connors, H., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30364-8 · Cited by 492
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Self-citationBariatric Surgery Survey 2018: Similarities and Disparities Among the 5 IFSO Chapters
Angrisani, L., Santonicola, A., Iovino, P., Ramos, A., Shikora, S., & Kow, L. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05207-7 · Cited by 468 · cited 1×
“52 RYGB results in 30% WL over the first post-operative year and a sustained 25–27% WL long-term.”
BackgroundFriedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Direct medical costs of obesity in the United States and the most populous states
Cawley, J., Biener, A., Meyerhoefer, C., Ding, Y., Zvenyach, T., Smolarz, B. G., & Ramasamy, A. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.20410 · Cited by 400
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397 · cited 1×
“In animal experiments, the effect of GLP-1 RAs on food intake is entirely dependent on central nervous sys-tem mechanisms, 99 and in humans this is supported by imaging experiments.”
BackgroundMiddeldorp, M. E., Pathak, R. K., Meredith, M., Mehta, A. B., Elliott, A. D., Mahajan, R., Twomey, D., Gallagher, C., Hendriks, J. M. L., Linz, D., et al. (2018) · EP Europace · doi:10.1093/europace/euy117 · Cited by 387 · cited 1×
“28 In general, weight regain is common after lifestyle interventions and approximately 80% of weight lost is expected to be regained over the next 5 years.”
BackgroundBellicha, A., van Baak, M. A., Battista, F., Beaulieu, K., Blundell, J. E., Busetto, L., Carraça, E. V., Dicker, D., Encantado, J., Ermolao, A., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13256 · Cited by 375 · cited 1×
“20 There is limited evidence on the effect of structured exercise on weight maintenance after weight-loss through diet, 20 but a recent clinical trial showed that the addition of a 52-week structured but flexible aerobic exercise programme after a low-calorie diet programme (mean WL 12”
BackgroundPeptide YY3–36 and Glucagon-Like Peptide-17–36 Inhibit Food Intake Additively
Neary, N. M., Small, C. J., Druce, M. R., Park, A. J., Ellis, S. M., Semjonous, N. M., Dakin, C. L., Filipsson, K., Wang, F., Kent, A. S., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0237 · Cited by 371 · cited 1×
“138,139 A long-acting PYY analogue in combination with semaglutide is now being assessed in a phase 2 study as treatment for obesity (NCT04969939).”
BackgroundTirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346
Mechanisms underlying weight loss after bariatric surgery
Miras, A. D., & le Roux, C. W. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.119 · Cited by 344 · cited 1×
“54 One of the potential mediators for the reduced appetite and food intake after bariatric surgery is the changes in the peripheral signals of body weight regulation (how the gut communicates with the brain) through alteration of gut anatomy.”
BackgroundHeymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338 · cited 1×
“141,142 In phase 2 clinical trials, 48 weeks of treatment with Bimagrumab in individuals living with obesity and T2D resulted in WL of 6.5% compared with 0.5% ( − 0.18 kg) in the placebo group, with a reduction in total body fat mass by 20.5% ( − 7.49 kg) and an increase in the lean mass by 3.6%,…”
InfluentialKadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · cited 1×
“114,115 Moreover, triple agonists, for example, GLP-1/GIP/glucagon agonists are being explored as potential treatments, although data from clinical trials are limited and in early stage.”
BackgroundComparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study
Arterburn, D., Wellman, R., Emiliano, A., Smith, S. R., Odegaard, A. O., Murali, S., Williams, N., Coleman, K. J., Courcoulas, A., Coley, R. Y., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2786 · Cited by 317
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314 · cited 1×
“116,117 In the context of T2D, the ability of GIP to stimulate insulin secretion and to ameliorate glycaemia is impaired.”
BackgroundSelf-citationAmbery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01751-7 · Cited by 278 · cited 1×
“114,115 Moreover, triple agonists, for example, GLP-1/GIP/glucagon agonists are being explored as potential treatments, although data from clinical trials are limited and in early stage.”
BackgroundNissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273 · cited 1×
“94 So, the cardiovascular safety of NB remains uncertain and will require further revaluation in adequately powered outcome trials.”
BackgroundCefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243 · cited 1×
“9,10 Until recently, pharmacotherapy to achieve and maintain ≥ 10% WL along with suitable tolerability and safety remained an unmet challenge.”
BackgroundDorling, J., Broom, D. R., Burns, S. F., Clayton, D. J., Deighton, K., James, L. J., King, J. A., Miyashita, M., Thackray, A. E., Batterham, R. L., et al. (2018) · Nutrients · doi:10.3390/nu10091140 · Cited by 235 · cited 6×
“Infusion of PYY3–36 in people with obesity causes a 30% reduction in food intake.”
BackgroundInfluentialDorling, J., Broom, D., Burns, S., Clayton, D., Deighton, K., James, L., King, J., Miyashita, M., Thackray, A., Batterham, R., et al. (2018) · doi:10.20944/preprints201807.0495.v1 · Cited by 235
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00188-7 · Cited by 226
Polidori, D., Sanghvi, A., Seeley, R. J., & Hall, K. D. (2016) · Obesity · doi:10.1002/oby.21653 · Cited by 209 · cited 2×
“30,32 RMR is mainly determined by body composition and accounts for 60–70% of 24 h total energy expenditure in humans.”
BackgroundWadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200
Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200
Self-citationBariatric Surgery and the Risk of New-Onset Atrial Fibrillation in Swedish Obese Subjects
Jamaly, S., Carlsson, L., Peltonen, M., Jacobson, P., Sjöström, L., & Karason, K. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.940 · Cited by 199 · cited 1×
“48,49 The benefits of bariatric surgery on reducing cardiovascular events, cardiovascular death, all-cause mortality and new onset heart failure compared with the non-surgical management are consistent across multiple observational, matched-cohort studies, especially in people with obesity and T2D.”
BackgroundGarvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care · doi:10.2337/dc19-1745 · Cited by 186
Svane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185 · cited 1×
“…RYGB and SG substantially increase the secretion of multiple satiety gut hormones after food intake, including GLP-1 and PYY and when the action of these hormones was blocked after RYGB, the food intake increased by 20%, 55 supporting a role of these gut hormones in early post-prandial satiety.”
BackgroundSelf-citationBossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179
The High and Rising Costs of Obesity to the US Health Care System
Biener, A. I., Cawley, J., & Meyerhoefer, C. D. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3968-8 · Cited by 172
Eliasson, B., Liakopoulos, V., Franzén, S., Näslund, I., Svensson, A.-M., Ottosson, J., & Gudbjörnsdottir, S. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00334-4 · Cited by 167 · cited 1×
“50,51 The most commonly performed bariatric procedures in the SOS study were gastric band and vertical banded gastroplasty with fewer patients undergoing Roux-en-Y gastric bypass (RYGB).”
BackgroundTillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164 · cited 2×
“133 Regarding triple agonists, evidence from experimental studies in animals suggests that the addition of GIP activity into dual GLP-1 and glucagon receptor agonism provides improved WL and glycaemic control while protecting against the diabetogenic risk of chronic glucagon agon-ism.”
BackgroundNeovius, M., Bruze, G., Jacobson, P., Sjöholm, K., Johansson, K., Granath, F., Sundström, J., Näslund, I., Marcus, C., Ottosson, J., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30437-0 · Cited by 161
Busetto, L., Bettini, S., Makaronidis, J., Roberts, C. A., Halford, J. C. G., & Batterham, R. L. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.01.002 · Cited by 159 · cited 4×
“30,31 The major drivers of weight regain after treatments that caused significant WL, include the persistence of a lower resting metabolic rate (RMR) (metabolic adaptation), the lower energy consumption during weight-bearing activities, and the persistence of increased appetite, probably mediated…”
BackgroundInfluentialAstbury, N. M., Aveyard, P., Nickless, A., Hood, K., Corfield, K., Lowe, R., & Jebb, S. A. (2018) · BMJ · doi:10.1136/bmj.k3760 · Cited by 155 · cited 1×
“18 However, at the 3-year follow-up, mean WL was 6.2 kg at the intervention arm compared with 2.7 kg at the usual care 19 with 24% of participants achieving ≥ 10% WL in the total diet replacement programme compared with 13% in usual care, suggesting that for this smaller number of patients this…”
MethodInfluentialWeight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
Sharretts, J., Galescu, O., Gomatam, S., Andraca-Carrera, E., Hampp, C., & Yanoff, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2003873 · Cited by 147 · cited 1×
“59 Nevertheless, the better understanding over the last years of the peripheral and central signals and mechanisms involved in WL and WL maintenance have contributed to the development of more effective and safe weight-loss medications.”
BackgroundBergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142 · cited 1×
“101,119,120 Unlike GLP-1, exogenous GIP infusion does not seem to reduce appetite and the combination of GLP-1 with GIP in people with and without T2D does not lead to any more significant appetite reduction compared with GLP-1 alone.”
ResultSelf-citationDouglas, J. A., King, J. A., Clayton, D. J., Jackson, A. P., Sargeant, J. A., Thackray, A. E., Davies, M. J., & Stensel, D. J. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.181 · Cited by 136 · cited 1×
“36,37 Regarding the chronic effects of aerobic exercise on appetite parameters, the results are inconsistent—however, a small increase in hunger at fasting state with a subsequent increase in satiety post-meal and without significant increase on energy intake has been found in a recent systematic…”
BackgroundSelf-citationFournier, B., Murray, B., Gutzwiller, S., Marcaletti, S., Marcellin, D., Bergling, S., Brachat, S., Persohn, E., Pierrel, E., Bombard, F., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06575-11 · Cited by 135
Kadowaki, T., Chin, R., Ozeki, A., Imaoka, T., & Ogawa, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00187-5 · Cited by 131
Pandey, A., Patel, K. V., Bahnson, J. L., Gaussoin, S. A., Martin, C. K., Balasubramanyam, A., Johnson, K. C., McGuire, D. K., Bertoni, A. G., Kitzman, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044865 · Cited by 127 · cited 1×
“25 These results suggest that ≥ 10% WL is associated with cardiovascular benefits for people with obesity and T2D.”
BackgroundBenefits of weight loss of 10% or more in patients with overweight or obesity: A review
Tahrani, A. A., & Morton, J. (2022) · Obesity · doi:10.1002/oby.23371 · Cited by 125 · cited 1×
“9,10 Until recently, pharmacotherapy to achieve and maintain ≥ 10% WL along with suitable tolerability and safety remained an unmet challenge.”
BackgroundPhentermine/Topiramate for the Treatment of Obesity
Smith, S. M., Meyer, M., & Trinkley, K. E. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r501 · Cited by 122 · cited 2×
“61 It is indicated for short-term use in weight management in USA, however, long-term data are not available.”
BackgroundIncidence of Hypoglycemia After Gastric Bypass vs Sleeve Gastrectomy: A Randomized Trial
Capristo, E., Panunzi, S., De Gaetano, A., Spuntarelli, V., Bellantone, R., Giustacchini, P., Birkenfeld, A. L., Amiel, S., Bornstein, S. R., Raffaelli, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01695 · Cited by 122
Iepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118 · cited 1×
“125 Currently, there is a lack of long-term data on the effectiveness and safety of obesity pharmacotherapies and on the improvement in obesity-related comorbidities (so far the longest follow-up study is for liraglutide 3 mg up to 3 years after initiation of treatment).”
BackgroundSelf-citationMarso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.063 · Cited by 118
Davies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13125 · Cited by 115
Self-citationDescribing the Weight‐Reduced State: Physiology, Behavior, and Interventions
Aronne, L. J., Hall, K. D., M. Jakicic, J., Leibel, R. L., Lowe, M. R., Rosenbaum, M., & Klein, S. (2021) · Obesity · doi:10.1002/oby.23086 · Cited by 113 · cited 4×
“30,31 The major drivers of weight regain after treatments that caused significant WL, include the persistence of a lower resting metabolic rate (RMR) (metabolic adaptation), the lower energy consumption during weight-bearing activities, and the persistence of increased appetite, probably mediated…”
BackgroundInfluentialSuccessful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101 · cited 1×
“31,40 43 However, as with most management techniques for chronic diseases, obesity relapses if the treatment is stopped.”
BackgroundSelf-citationAlonso, A., Bahnson, J. L., Gaussoin, S. A., Bertoni, A. G., Johnson., K. C., Lewis, C. E., Vetter, M., Mantzoros, C. S., Jeffery, R. W., & Soliman, E. Z. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.026 · Cited by 97 · cited 1×
“8 24–26 However, in a post-hoc analysis, those participants in the intervention arm who lost ≥ 10% of their baseline body weight during the first year (early good responders) had 20% lower risk for cardiovascular events over a 10 years follow-up period.”
BackgroundSurgical obesity treatment and the risk of heart failure
Jamaly, S., Carlsson, L., Peltonen, M., Jacobson, P., & Karason, K. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz295 · Cited by 77 · cited 1×
“48,49 The benefits of bariatric surgery on reducing cardiovascular events, cardiovascular death, all-cause mortality and new onset heart failure compared with the non-surgical management are consistent across multiple observational, matched-cohort studies, especially in people with obesity and T2D.”
BackgroundAmylin as a Future Obesity Treatment
Dehestani, B., Stratford, N. R., & Roux, C. W. L. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21071 · Cited by 72 · cited 1×
“129 It functions as a satiety signal, acting upon brain regions involved in both homeostatic and hedonic appetite regulation; it also slows the gastric emptying, and thereby suppresses post-prandial glucagon responses to meals.”
BackgroundAhlin, S., Peltonen, M., Sjöholm, K., Anveden, Å., Jacobson, P., Andersson‐Assarsson, J. C., Taube, M., Larsson, I., Lohmander, L. S., Näslund, I., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13020 · Cited by 68
Farr, O. M., Upadhyay, J., Rutagengwa, C., DiPrisco, B., Ranta, Z., Adra, A., Bapatla, N., Douglas, V. P., Douglas, K. A. A., Nolen‐Doerr, E., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13827 · Cited by 64 · cited 1×
“100,101 approved for adolescents ≥ 12 years old.”
BackgroundBergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62 · cited 1×
“101,119,120 Unlike GLP-1, exogenous GIP infusion does not seem to reduce appetite and the combination of GLP-1 with GIP in people with and without T2D does not lead to any more significant appetite reduction compared with GLP-1 alone.”
ResultSelf-citationBeaulieu, K., Blundell, J. E., van Baak, M. A., Battista, F., Busetto, L., Carraça, E. V., Dicker, D., Encantado, J., Ermolao, A., Farpour‐Lambert, N., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13251 · Cited by 59
Four-year physical activity levels among intervention participants with type 2 diabetes
UNICK, J. L., GAUSSOIN, S. A., HILL, J. O., JAKICIC, J. M., BOND, D. S., HELLGREN, M., JOHNSON, K. C., PETERS, A. L., CODAY, M., KITZMAN, D. W., et al. (2016) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001054 · Cited by 52 · cited 1×
“22 The largest trial assessing the effectiveness of intensive lifestyle interventions was the Look AHEAD study, where 5145 people with obesity and T2D were randomized to receive intensive lifestyle support (intervention group) vs. a structured education programme (usual care group).”
BackgroundPhysiology of Energy Expenditure in the Weight‐Reduced State
Ravussin, E., Smith, S. R., & Ferrante, A. W. (2021) · Obesity · doi:10.1002/oby.23095 · Cited by 48 · cited 3×
“33,34 In addition, most people who manage to lose ≥ 10% of their body weight through low-calorie diet experience an increase in their appetite compared with baseline ( Figure 1 ).”
BackgroundNaltrexone/bupropion for the Treatment of Obesity and Obesity With Type 2 Diabetes
Apovian, C. M. (2016) · Future Cardiology · doi:10.2217/fca.15.79 · Cited by 47
Cardiovascular Safety During and After Use of Phentermine and Topiramate
Ritchey, M. E., Harding, A., Hunter, S., Peterson, C., Sager, P. T., Kowey, P. R., Nguyen, L., Thomas, S., Cainzos-Achirica, M., Rothman, K. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01010 · Cited by 42
Obesity and responsibility: Is it time to rethink agency?
Grannell, A., Fallon, F., Al‐Najim, W., & le Roux, C. (2021) · Obesity Reviews · doi:10.1111/obr.13270 · Cited by 41 · cited 1×
“30,32 So, if we consider obesity as a disease of dysregulated appetite where the increased hunger and/or the reduced satiety are the main symptoms, 39 then lifestyle interventions which usually result in increase of appetite may not effectively treat the symptoms of the underlying disease and this…”
BackgroundKolotkin, R. L., Fujioka, K., Wolden, M. L., Brett, J. H., & Bjorner, J. B. (2016) · Clinical Obesity · doi:10.1111/cob.12146 · Cited by 40
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35 · cited 1×
“118 Regarding the effect of GIP on appetite, it has only been assessed in a few acute studies in humans.”
BackgroundCracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34 · cited 1×
“111 Tirzepatide is the first dual co-agonist (acting on GLP-1/GIP receptors) which has been approved for treatment of T2D based on the findings of the clinical trials from the SURPASS programme.”
MethodTan, T. M. ‐., Minnion, J., Khoo, B., Ball, L., Malviya, R., Day, E., Fiorentino, F., Brindley, C., Bush, J., & Bloom, S. R. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14358 · Cited by 34
The diverse effects of brain glucagon‐like peptide 1 receptors on ingestive behaviour
Williams, D. L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15535 · Cited by 34
Halseth, A. E., Shan, K., Gilder, K. M., Malone, M., Acevedo, L. M., & Fujioka, K. (2018) · Obesity Science & Practice · doi:10.1002/osp4.156 · Cited by 30 · cited 1×
“92,93 The WL achieved with NB 32/360 was also associated with improvements in some cardiometabolic risk factors such as HDL and hepatic insulin resistance markers, however the systolic blood pressure (SBP) and diastolic blood pressure improved more in the placebo group compared with the NB 32/360.”
BackgroundKolotkin, R. L., Gadde, K. M., Peterson, C. A., & Crosby, R. D. (2016) · Quality of Life Research · doi:10.1007/s11136-015-1153-x · Cited by 24
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, B. C. E., & Tan, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0119 · Cited by 23 · cited 1×
“116,117 In the context of T2D, the ability of GIP to stimulate insulin secretion and to ameliorate glycaemia is impaired.”
BackgroundHolst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23 · cited 2×
“101 On this background, it came as a surprise that the GLP-1/GIP co-agonist, tirzepatide, had glucose-lowering and weight-loss activities that exceeded those of GLP-1 RA comparators in clinical trials.”
BackgroundResultSelf-citationKolotkin, R. L., Chen, S., Klassen, P., Gilder, K., & Greenway, F. L. (2015) · Clinical Obesity · doi:10.1111/cob.12108 · Cited by 18 · cited 1×
“92,93 The WL achieved with NB 32/360 was also associated with improvements in some cardiometabolic risk factors such as HDL and hepatic insulin resistance markers, however the systolic blood pressure (SBP) and diastolic blood pressure improved more in the placebo group compared with the NB 32/360.”
BackgroundAstbury, N. M., Edwards, R. M., Ghebretinsea, F., Shanyinde, M., Mollison, J., Aveyard, P. N., & Jebb, S. A. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00915-1 · Cited by 13 · cited 2×
“19 Structured exercise programmes can usually add 1.5–3.5 kg WL to a dietary intervention, and they have multiple other health benefits such as improvement in body composition, physical function, and cardiorespiratory fitness.”
BackgroundMethodInfluential
Research works printed but not linked: 2
- Aronne, 2021, Describing the weight-reduced state: physiology, Obesity (Silver Spring, 29, S9
- De Silva, 2011, The gut hormones PYY, Cell Metab, 14, 3
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Multiple other molecules (including combinations of entero-pancreatic hormones and oral GLP-1 RA) are in late phase clinical trials as potential obesity treatments, leading to WL that approaches the ef fi cacy of bariatric surgery [101].”
Self-citationEfficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Self-citationMłynarska, E., Bojdo, K., Bulicz, A., Frankenstein, H., Gąsior, M., Kustosik, N., Rysz, J., & Franczyk, B. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100787 · Cited by 105
“Although dedicated cardiovascular outcome trials in people with obesity are still needed, current data suggest no increased cardiovascular risk [119].”
Domingo, E., Marqués, P., Francisco, V., Piqueras, L., & Sanz, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107058 · Cited by 73
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
“Similarly, lifestyle interventions are key for the management of obesity; however, even the implementation of most intensive programmes translates into 5–10% BW loss with a tendency for weight regain [31].”
Background
Metadata
- Authors
- Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J.
- Affiliations
- University of Leicester (GB)
- Diabetes Complications Research Centre, Conway Institute, University College Dublin , Dublin 4 , Ireland
- University of Copenhagen (DK)
- Corresponding author
- Papamargaritis, Dimitris
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-11-30
- Volume
- 119
- Issue
- 18
- Pages
- 2825-2842
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC10874276
- OpenAlex
- W4310416488
- Semantic Scholar
- c9c62a64b6cead4b21fbd76ca890be39591b68cc
- Cited by
- 73
- References
- 141
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 31 · 2023: 11
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Cardiovascular Research (publishedVersion, public-domain)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Ulster University Research Portal (Ulster University) (submittedVersion, public-domain)
- Figshare (submittedVersion, cc-by)
- Funders
- Leicester NIHR Biomedical Research Centre
- National Institute of Clinical Research Clinical Lectureship
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, obesity pharmacotherapy, weight loss, appetite regulation, bariatric surgery, semaglutide, GLP-1 receptor agonists, tirzepatide, glucose-dependent insulinotropic polypeptide, lifestyle intervention
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Appetite, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.